Gliquidone compound preparation capable of reducing renal damage

A technology of glibaquinone and compound preparations, which is applied in the field of diabetes pharmaceutical preparations, can solve the problems that the quality of life of patients treated with the disease is not very good, the protection of kidneys and blood vessels is not obvious, and the body develops drug resistance, etc. The effect of quality of life, avoiding the decline of filtration capacity, and reducing kidney damage

Active Publication Date: 2017-02-01
BEIJING WANHUI DOUBLE CRANE PHARMA
View PDF3 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0010] Although the ingredients of Western medicine are clear and the mechanism of action is clear, the disadvantage is that with the prolongation of the medicinal time, the body will develop drug resistance, which will eventually lead to secondary failure. burden, does not have much benefit to the treatment of the disease and the long-term quality of life of the patien...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Gliquidone compound preparation capable of reducing renal damage
  • Gliquidone compound preparation capable of reducing renal damage

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] The preparation of embodiment 1 gliquidone compound capsule

[0033] Weigh the dried Panax notoginseng root, put it into the extraction container after crushing, pour 70% (v / v) ethanol into it according to the ratio of material to liquid (mass) 5:4, as a desorbent, soak the Panax notoginseng powder, and desorb at room temperature for 30 minutes . Then pour 8 times the amount of distilled water with a temperature of 45°C into the fully soaked medicinal materials, and quickly reduce the pressure to -0.084MPa, so that small bubbles will emerge from the inside of the Panax notoginseng powder, and achieve internal boiling and extraction for 4 minutes, then vacuum filter. Get the extracted filter residue (i.e. medicinal residue), carry out the second extraction according to the same conditions as above-mentioned first extraction, only change the amount of distilled water into 5 times of the filter residue quality. The two extracts of Panax notoginseng were combined, concentr...

Embodiment 2

[0038] Embodiment 2 GLiquidone Compound Capsule Drug Efficacy Detection

[0039] 1. DN model copy

[0040] SPF grade male SD rats were selected as experimental animals, fed a high-energy diet (high-sugar and high-fat diet) supplemented with a small dose of intraperitoneal injection of streptozotocin, induced non-insulin-dependent (type 2) diabetes, and detected blood sugar ≥ When it is above 16.7mmol / L, it is determined that the diabetic rat model is successfully established. The diabetic rat model progressed to diabetic nephropathy (DN) according to the natural course of the disease, and the fasting blood glucose was detected to be ≥16.7mmol / L, the urinary protein excretion rate was >20μg / min, and the urine volume was 150% of the normal amount, which was determined to be the replication of the diabetic nephropathy rat model success.

[0041] 2. Experimental medication and group feeding

[0042] Referring to the literature "Observation on the Curative Effect of GLiquidone H...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a gliquidone compound preparation capable of reducing renal damage. The gliquidone compound preparation capable of reducing renal damage is prepared from main drugs and auxiliary materials, and is characterized in that the main drugs are prepared from 20-30% (w/w) of gliquidone, 15-25% (w/w) of ligustrazine and the balance of radix notoginseng extract, wherein the dosage of the radix notoginseng extract is counted based on the mass of dry powder; the radix notoginseng extract is extracted from radix notoginseng, and comprises four types of substances, namely saponin, flavone, amino acid and polyose. The gliquidone compound preparation is supplemented with the radix notoginseng extract and the ligustrazine, so that the gliquidone dosage is reduced, and further the influence of the gliquidone on the renal function of a patient is reduced; the three types of drugs achieve a synergetic effect, so that the blood glucose is reduced, functions of glomeruli are protected, the glomerular filtration capability reduction is prevented, and the blood fat is regulated, so that the gliquidone compound preparation is more applicable to patients suffering from diabetic nephropathy.

Description

technical field [0001] The invention relates to the technical field of diabetes pharmaceutical preparations, in particular to a compound preparation of gliquidone that reduces kidney damage. Background technique [0002] Diabetes mellitus is a group of lifelong metabolic diseases characterized by chronic hyperglycemia caused by multiple etiologies. Long-term high blood sugar, damage to large blood vessels and microvessels and endanger the heart, brain, kidneys, peripheral nerves, eyes, feet, etc. According to the statistics of the World Health Organization, there are more than 100 complications of diabetes, which is the most known type of complications disease. More than half of diabetes deaths are caused by cardiovascular and cerebrovascular diseases, and 10% are caused by nephropathy. [0003] Currently commonly used oral hypoglycemic drugs are divided into insulin secretagogues, metformin, α-glucosidase inhibitors, thiazolidinedione derivatives, DDP-4 enzyme inhibitors,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K36/258A61K31/64A61K31/4965A61K9/48A61K47/38A61K47/26A61P3/10A61P13/12A61P3/06
CPCA61K9/4858A61K9/4866A61K31/4965A61K31/64A61K36/258A61K2236/331A61K2300/00
Inventor 魏福生王义波陈利敏潘湘红钟皓宋鸿睿孟晓雪郑啸
Owner BEIJING WANHUI DOUBLE CRANE PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap